Stefan Cohen

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Ambiq Micro, a technology leader in ultra-low-power semiconductor solutions for edge artificial intelligence, on its $96 million initial public offering (IPO).

Cooley advised Kudu Dynamics, a company developing state-of-the-art cyber capabilities and nonkinetic effects against a variety of military-relevant systems, on its sale to Leidos (NYSE: LDOS), an industry and technology leader serving government and commercial customers with smarter, more efficient digital and mission innovations.

Cooley advised Nuclei in its sale to Proofpoint, a leading cybersecurity and compliance company. Nuclei is a US-based technology company specializing in compliance archiving and artificial intelligence-driven data enrichment for modern workplace communications. Partner Ariel Rom led the Cooley team advising Nuclei.

Cooley advised Takara Bio, a global biotechnology and life sciences company headquartered in Shiga, Japan, on its acquisition of Curio Bioscience, a pioneering company in the field of spatial genomics.